市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | SUNHO BIO-B | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -1.00 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| SUNHO BIO-B | 1 B | - | - | 2.14 |
| AKESO | 111 B | - | - | 15.36 |
| PHARMARON | 56 B | 0.92% | 22.04 | 2.39 |
| INNOVENT BIO | 161 B | - | 128.90 | 11.07 |
| WUXI BIO | 136 B | - | 30.50 | 2.72 |
| SINO BIOPHARM | 126 B | 1.15% | 29.38 | 3.35 |
|
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合